Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acyclovir prophylaxis from 28 to 36 weeks in HSV-2-seropositive pregnant women in Uganda
PACTR201311000558197Not yet recruiting
- Sponsor
- MEPI
- Start
- Oct 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Trial of aciclovir in Genital Herpes Type 2 (HSV-2) (2 arms), sponsored by MEPI. Primary endpoints: Occurrence of preterm prelabour rupture of membranes and Preterm delivery. Planned start Oct 2013; status: not yet recruiting.
02
Drugs
aciclovir
03
Conditions
Genital Herpes Type 2 (HSV-2)
Beyond the preview
Go deeper on PACTR201311000558197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201311000558197.